Compare Bristol-Myers Squibb Co (BMY) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Anheuser-Busch Inbev SA — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while Anheuser-Busch Inbev SA trades at $79.59 (market cap $159.01B). The key difference: Anheuser-Busch Inbev SA is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | BUD | |
|---|---|---|
Market Cap | $129.94B | $159.01B |
Sector | Health | Consumer Staples |
52-Week High | $65.89 | $86.48 |
52-Week Low | $42.60 | $57.93 |
Enterprise Value | $163.92B | $223.42B |
Dividend Yield | 3.96% | 1.67% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
